NAFLD/NASH incidence in the US maybe is 50% higher.. In this recent podcast the key opinion leaders in the industry touch based on the prevalence of NASH. As per speakers the NAFLD/NASH incidence in the US maybe is 50% higher than current estimates also they described recent none invasive testing as a "breakthrough" due to the recent FDA approval of the enhanced liver fibrosis tests(blood tests).
"The Biggest NAFLD/NASH story of the summer? Each had different ideas. To NASH kNOWledge President and Founder Tony Villiotti, the biggest story combined two recent publications that cross-validated the ideas that NAFLD and NASH incidence in the US maybe be 50% higher than is conventionally estimated...and that less than 10% of people with disease know about their conditions. To Fatty Liver Foundation President Wayne Eskridge, the FDA's appoval of Siemens' ELF test signalled both a breakthrough and a promise for non-invasive testing. Finally, Global Liver Institute Founder and CEO Donna Cryer considered the overall movement toward her goal of "beyond the biopsy" the story and the various data points, ranging from the new EASL guidelines to a lessened need for transplant hepatologists in training to perform as many biopsies during their training, as proof of the larger issue. In different ways, each conversation focused on the need to improve and expand patient and professional education."
https://youtu.be/3csr-pG1nqA